Skip to Main Content
Contribute Try STAT+ Today

When the long-awaited trial of former Theranos CEO Elizabeth Holmes opens at the end of this month, expect a showdown between defense attorneys and federal prosecutors who have accused her of perpetrating one of the biggest corporate frauds in recent U.S. history.

But perhaps even more striking will be the collision it spotlights between the “move fast and break things” culture of Silicon Valley and the more cautious cadence of health care, where the first rule is to do no harm. Legal experts said the verdict will turn on a narrow set of facts, but its fallout will be more widely felt in the burgeoning biotech and digital health sectors where entrepreneurs are actively raising huge sums of money based on products that often have little evidence behind them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment